An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis

Trial Profile

An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2016

At a glance

  • Drugs F 652 (Primary)
  • Indications Alcoholic hepatitis
  • Focus Adverse reactions
  • Acronyms TREAT 008
  • Most Recent Events

    • 29 Apr 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 29 Apr 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 29 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top